530 related articles for article (PubMed ID: 17708739)
1. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
Cronstein BN
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
[TBL] [Abstract][Full Text] [Related]
2. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
4. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
Nakahara H; Nishimoto N
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
Ohsugi Y
Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
Kavanaugh A
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S16-20. PubMed ID: 17708740
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
11. [A humanized anti-IL-6 receptor antibody(MRA) in RA therapy].
Hagihara K; Nishimoto N; Yoshizaki K
Nihon Rinsho; 2002 Dec; 60(12):2401-7. PubMed ID: 12510369
[TBL] [Abstract][Full Text] [Related]
12. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
Nasonov EL
Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6: from identification of the cytokine to development of targeted treatments.
Assier E; Boissier MC; Dayer JM
Joint Bone Spine; 2010 Dec; 77(6):532-6. PubMed ID: 20869898
[TBL] [Abstract][Full Text] [Related]
14. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
15. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting interleukin-6 in rheumatoid arthritis.
Choy E
Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
Snir A; Kessel A; Haj T; Rosner I; Slobodin G; Toubi E
Clin Exp Rheumatol; 2011; 29(4):697-700. PubMed ID: 21813064
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 in the pathogenesis of rheumatoid arthritis.
Park JY; Pillinger MH
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S4-10. PubMed ID: 17708744
[TBL] [Abstract][Full Text] [Related]
19. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]